Literature DB >> 8809232

Current concepts of the etiology and pathogenesis of ulcerative colitis and Crohn's disease.

R B Sartor1.   

Abstract

Although the causes, events initiating and triggering inflammation, and the precise immunoregulatory defects of IBD are still not known, investigations have provided a better understanding of the mechanisms of perpetuation of inflammation, genetic susceptibility, tissue injury, and symptoms. Ulcerative colitis and Crohn's disease are related disorders that probably share susceptibility genes and have similar nonspecific inflammatory mediator profiles. These diseases, however, almost certainly have different causes and respond to different antigenic stimuli. It is probable that both ulcerative colitis and Crohn's disease represent heterogenic groups of diseases that share similar mechanisms of tissue damage but have different initiating events and immunoregulatory abnormalities. Rodent models demonstrate that a wide variety of initial injuries or perturbations of immunoregulatory pathways can lead to similar phenotypes of intestinal injury, and human studies show evidence of genetic heterogeneity. It is equally apparent from these models that initiating and perpetuating mechanisms are entirely distinct and that the intestine has a remarkable ability to heal. Chronicity of disease depends on continued exposure to toxic luminal components, most commonly of bacterial origin, and genetically determined host susceptibility. Precise mechanisms of differential genetic susceptibility remain unclear, but defective down-regulation of inflammation is consistent with clinical and experimental observations. The author proposes the following sequence of events (Fig. 9). Nonspecific intestinal inflammation can be induced by a wide variety of enteric infections or ingested toxins. Resultant increased mucosal permeability leads to enhanced uptake of toxic luminal bacterial products, which potentiate local injury. The vast majority of hosts respond to these injurious events by promptly down-regulating the inflammatory response and rapidly healing the mucosal damage without residual scarring. The genetically susceptible host, however, who lacks the ability to suppress the inflammatory response efficiently, has inappropriate amplification of the immune cascade. In response to constant exposure to phlogistic luminal constituents, these patients develop an unrestrained inflammatory response, leading to tissue destruction, chronic inflammation, and fibrosis. Thus, IBD is caused by a genetically determined defective down-regulation of inflammation driven by ubiquitous antigens. Luminal anaerobic bacterial antigens are the stimuli in Crohn's disease, but ulcerative colitis may be caused by functionally abnormal aerobic bacteria or primary defects in epithelial cell physiology. Spontaneous or therapy-induced remissions can be achieved, but the risk of reactivation of inflammation is high because of the frequent exposure to triggering episodes that can reignite the inflammatory cascade. [formula: see text] This theory suggests that the intestine is in a constant state of controlled inflammation, mediated by a balance between aggressive luminal forces and host protective mechanisms (Fig. 10). This delicate balance can be deranged by any number of environmental triggering events and is in dysequilibrium in IBD. Amplification of the inflammatory response activates effector cells and cascades of soluble inflammatory molecules, which mediate tissue injury and physiologic responses leading to symptoms of IBD. These relatively nonspecific events are the target of most current therapeutic agents, which can inhibit but not completely block intestinal inflammation because of the overwhelming number of parallel pathways involved. Specific inhibition of selected effector molecules is intellectually intriguing but is less likely to paralyze the inflammatory response during clinically apparent inflammation than is blockade of key immunoregulatory cells and molecules. Better understanding of initiating, perpetuating, and immunoregulatory mechanisms should provide more

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 8809232

Source DB:  PubMed          Journal:  Gastroenterol Clin North Am        ISSN: 0889-8553            Impact factor:   3.806


  87 in total

Review 1.  Clinical aspects and pathophysiology of inflammatory bowel disease.

Authors:  Barbara A Hendrickson; Ranjana Gokhale; Judy H Cho
Journal:  Clin Microbiol Rev       Date:  2002-01       Impact factor: 26.132

2.  Bifidobacterium lactis attenuates onset of inflammation in a murine model of colitis.

Authors:  David Philippe; Laurent Favre; Francis Foata; Oskar Adolfsson; Genevieve Perruisseau-Carrier; Karine Vidal; Gloria Reuteler; Johanna Dayer-Schneider; Christoph Mueller; Stéphanie Blum
Journal:  World J Gastroenterol       Date:  2011-01-28       Impact factor: 5.742

3.  An endogenously anti-inflammatory role for methylation in mucosal inflammation identified through metabolite profiling.

Authors:  Douglas J Kominsky; Simon Keely; Christopher F MacManus; Louise E Glover; Melanie Scully; Colm B Collins; Brittelle E Bowers; Eric L Campbell; Sean P Colgan
Journal:  J Immunol       Date:  2011-04-22       Impact factor: 5.422

4.  Quantitative and functional characteristics of intestinal-homing memory T cells: analysis of Crohn's disease patients and healthy controls.

Authors:  A L Hart; M A Kamm; S C Knight; A J Stagg
Journal:  Clin Exp Immunol       Date:  2004-01       Impact factor: 4.330

5.  Chronic recurrent multifocal osteomyelitis associated with chronic inflammatory bowel disease in children.

Authors:  A Bousvaros; M Marcon; W Treem; P Waters; R Issenman; R Couper; R Burnell; A Rosenberg; E Rabinovich; B S Kirschner
Journal:  Dig Dis Sci       Date:  1999-12       Impact factor: 3.199

Review 6.  Wound healing and fibrosis in intestinal disease.

Authors:  F Rieder; J Brenmoehl; S Leeb; J Schölmerich; G Rogler
Journal:  Gut       Date:  2007-01       Impact factor: 23.059

Review 7.  Nutritional modulation of the inflammatory response in inflammatory bowel disease--from the molecular to the integrative to the clinical.

Authors:  Gary E Wild; Laurie Drozdowski; Carmela Tartaglia; M Tom Clandinin; Alan B R Thomson
Journal:  World J Gastroenterol       Date:  2007-01-07       Impact factor: 5.742

Review 8.  Probiotics and medical nutrition therapy.

Authors:  Amy C Brown; Ana Valiere
Journal:  Nutr Clin Care       Date:  2004 Apr-Jun

9.  Protective effect of lactulose on dextran sulfate sodium-induced colonic inflammation in rats.

Authors:  György Rumi; Ryouichi Tsubouchi; Mitsuaki Okayama; Shinichi Kato; Gyula Mózsik; Koji Takeuchi
Journal:  Dig Dis Sci       Date:  2004-09       Impact factor: 3.199

10.  Granulocyte-macrophage colony-stimulating factor and interleukin-3 potentiate interferon-gamma-mediated endothelin production by human monocytes: role of protein kinase C.

Authors:  B Salh; K Hoeflick; W Kwan; S Pelech
Journal:  Immunology       Date:  1998-11       Impact factor: 7.397

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.